Shanghai Qiaer's lead product is rh-Apo21, a pioneering gene therapy drug used to treat certain forms of cancer. Rh-Apo21 is nearing the end of phase I clinical trials, which are expected to be completed at the end of April 2006.
"Gene therapy is the future of the pharmaceutical industry, holding the promise to treat some of the most difficult health problems facing the world today," said Biao Jin, Aida's CEO. "We are pleased to be able to tier our pharmaceutical offerings to include antibiotics, cardiovascular, antineoplastic drugs and genetic drug therapies."